ImmuneID is a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases.
ImmuneID uses its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
ImmuneID was founded in 2020 by Longwood Fund, based on technology developed by Stephen Elledge, Ben Larman, and Tomasz Kula. The company is headquartered in Cambridge, Massachusetts
ImmuneID is employing our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.
ImmuneID’s platform is a robust, patented, and well-validated system that makes use of next generation sequencing, robotic automation, and artificial intelligence to interrogate and ultimately drug the immune system.
The Elledge Lab has optimized the platform through years of intensive research and development resulting in multiple articles in leading journals such as Science and Cell.
ImmuneID has raised $17M in a new funding on Feb 17, 2021. The round was led by founding investor Longwood Fund, as well as Arch Venture Partners, Pitango HealthTech, In-Q-Tel, Xfund, and others.